Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Philippe Colucci"'
Autor:
Deniz Ozdin, Naveen Sharma, Jorge Lujan-Zilbermann, Philippe Colucci, Isadore Kanfer, Murray P. Ducharme
Publikováno v:
Journal of Pharmacy & Pharmaceutical Sciences, Vol 21, Iss 1 (2018)
Purpose: As per the US FDA guidance issued on June 2, 1995, the establishment of bioequivalence for topical dermatologic corticosteroids is based on comparing the pharmacodynamic (PD) effects of Test and Reference products at the dose duration corres
Externí odkaz:
https://doaj.org/article/ebcc94ded581475cbc5e658269794438
Publikováno v:
Asian Journal of Pharmaceutical Sciences, Vol 10, Iss 6, Pp 461-471 (2015)
Orally inhaled drug products (OIPs), such as corticosteroids and bronchodilators, are at the forefront of asthma and chronic obstructive pulmonary disease treatments, two diseases that afflict worldwide populations. Introducing generics of these prod
Externí odkaz:
https://doaj.org/article/c64b047788064748b383cb060f3f0c15
Publikováno v:
Journal of Pharmacy & Pharmaceutical Sciences, Vol 14, Iss 2 (2011)
In noncompartmental analysis, poor characterization of the terminal elimination rate constant (Kel) will lead to biased results for half-life and total exposure (AUCinf), providing incorrect relative bioavailability and bioequivalence conclusions. We
Externí odkaz:
https://doaj.org/article/51c08b3e5a5c4cb7844fce04e6d1fb6b
Autor:
Isadore Kanfer, Deniz Ozdin, Philippe Colucci, Jorge Lujan-Zilbermann, Naveen Sharma, Murray P. Ducharme
Publikováno v:
Journal of Pharmacy & Pharmaceutical Sciences, Vol 21, Iss 1 (2018)
Purpose : As per the US FDA guidance issued on June 2, 1995, the establishment of bioequivalence for topical dermatologic corticosteroids is based on comparing the pharmacodynamic (PD) effects of Test and Reference products at the dose duration corre
Autor:
William Tracewell, Murray P. Ducharme, Mona Darwish, Laura Rabinovich-Guilatt, Sally Selim, Philippe Colucci, Ofer Spiegelstein, Richard Malamut, Ronghua Yang, Mary Bond, Philmore Robertson
Publikováno v:
Clinical Drug Investigation. 37:1153-1163
Food intake can alter the pharmacokinetics of certain medications, including changes in their oral bioavailability, which is of particular concern for extended-release (ER) opioids because of the high drug loads. Two randomized, open-label studies as
Publikováno v:
Asian Journal of Pharmaceutical Sciences, Vol 10, Iss 6, Pp 461-471 (2015)
Orally inhaled drug products (OIPs), such as corticosteroids and bronchodilators, are at the forefront of asthma and chronic obstructive pulmonary disease treatments, two diseases that afflict worldwide populations. Introducing generics of these prod
Publikováno v:
Therapeutic Drug Monitoring. 33:355-361
To assess the pharmacokinetic equivalence of a new soft capsule formulation of levothyroxine versus a marketed reference product and to assess the soft capsule formulated with stricter potency guidelines versus the capsule before the implementation o
Publikováno v:
Therapeutic drug monitoring. 33(5)
Background There has been an increased focus on population pharmacokinetics (PK) to improve the drug development process since the "Critical Path paper" by the Food and Drug Administration. This increased interest has given rise to additional algorit
Publikováno v:
Journal of Pharmacy & Pharmaceutical Sciences, Vol 14, Iss 2 (2011)
In noncompartmental analysis, poor characterization of the terminal elimination rate constant (Kel) will lead to biased results for half-life and total exposure (AUCinf), providing incorrect relative bioavailability and bioequivalence conclusions. We
The purpose of this study was to determine the effect of a single dose of 300 mg of ritonavir on the plasma pharmacokinetics (PK) of a single dose of 20 mg of elvucitabine when the two drugs were coadministered in healthy subjects. In a three-way cro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc2f157e43e6dcd0cda1007263e98704
https://europepmc.org/articles/PMC2630647/
https://europepmc.org/articles/PMC2630647/